HTLV-1 study tracks survival to unlock secrets of rare Virus-Linked cancer
NCT ID NCT05237245
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 69 people infected with HTLV-1, some of whom have developed a rare blood cancer called adult T-cell leukemia/lymphoma. Researchers will track survival rates over 2 and 5 years, along with viral levels and genetic markers. The goal is to better understand how the virus causes disease and how patients fare over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide a clearer picture of how HTLV-1 affects the body over time, helping doctors predict outcomes and plan better care.
- What could go wrong
- This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly lead to a cure or new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HTLV-1 ADULT T-CELL LYMPHOMA / LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.